These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2909443)

  • 1. Tamoxifen therapy in advanced/recurrent endometrial carcinoma.
    Quinn MA; Campbell JJ
    Gynecol Oncol; 1989 Jan; 32(1):1-3. PubMed ID: 2909443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VM-26-vincristine-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent endometrial carcinoma.
    Sorbe B; Wolmesjö E; Frankendal B
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):343-8. PubMed ID: 2915860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay.
    Stratton JA; Mannel RS; Rettenmaier MA; Berman ML; DiSaia PJ
    Gynecol Oncol; 1989 Jan; 32(1):55-9. PubMed ID: 2535831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.
    Campora E; Vidali A; Mammoliti S; Ragni N; Conte PF
    Eur J Gynaecol Oncol; 1990; 11(3):181-3. PubMed ID: 2209636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy with single agents for advanced or recurrent endometrial carcinoma.
    Thigpen T
    Cancer Treat Res; 1989; 49():93-106. PubMed ID: 2577205
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.
    Hoffman MS; Roberts WS; Cavanagh D; Praphat H; Solomon P; Lyman GH
    Gynecol Oncol; 1989 Oct; 35(1):75-7. PubMed ID: 2477317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia.
    Carlson JA; Allegra JC; Day TG; Wittliff JL
    Am J Obstet Gynecol; 1984 May; 149(2):149-53. PubMed ID: 6232850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
    Kline RC; Freedman RS; Jones LA; Atkinson EN
    Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen treatment of advanced endometrial carcinoma. A phase II study.
    Hald I; Salimtschik M; Mouridsen HT
    Eur J Gynaecol Oncol; 1983; 4(2):83-7. PubMed ID: 6873094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
    Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
    Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate.
    Lovecchio JL; Averette HE; Lichtinger M; Townsend PA; Girtanner RW; Fenton AN
    Obstet Gynecol; 1984 Apr; 63(4):557-60. PubMed ID: 6538327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma.
    Thigpen T; Vance RB; Balducci L; Blessing J
    Cancer; 1981 Jul; 48(2 Suppl):658-65. PubMed ID: 7023669
    [No Abstract]   [Full Text] [Related]  

  • 13. Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone.
    Quinn MA; Campbell JJ; Murray R; Pepperell RJ
    Aust N Z J Obstet Gynaecol; 1981 Nov; 21(4):226-9. PubMed ID: 6951563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Burke TW; Stringer CA; Morris M; Freedman RS; Gershenson DM; Kavanagh JJ; Edwards CL
    Gynecol Oncol; 1991 Mar; 40(3):264-7. PubMed ID: 2013451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma.
    Bonte J; Ide P; Billiet G; Wynants P
    Gynecol Oncol; 1981 Apr; 11(2):140-61. PubMed ID: 6783481
    [No Abstract]   [Full Text] [Related]  

  • 16. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.
    Rendina GM; Donadio C; Fabri M; Mazzoni P; Nazzicone P
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):285-91. PubMed ID: 6235140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
    Thigpen T; Brady MF; Homesley HD; Soper JT; Bell J
    J Clin Oncol; 2001 Jan; 19(2):364-7. PubMed ID: 11208827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma.
    Boadle DJ; Tattersall MH
    Aust N Z J Obstet Gynaecol; 1987 Nov; 27(4):341-2. PubMed ID: 3453676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study.
    Thigpen JT; Kronmal R; Vogel S; Hynes HE; Nahhas W; Belt RJ; Balcerzak SP; Epstein RB; Costanzi JJ
    Am J Clin Oncol; 1987 Oct; 10(5):429-31. PubMed ID: 3661494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megestrol acetate in the management of advanced endometrial carcinoma.
    Wait RB
    Obstet Gynecol; 1973 Jan; 41(1):129-36. PubMed ID: 4682608
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.